GMS hygiene and infection control · 2026
Randomized controlled clinical trial of the impact of combined application of rhamnosus probiotics and oral nystatin on the colonization of intestinal Candida albicans in low birth weight neonates <2,500 grams.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vakiliamini Mazyar, Habibi Reza, Zarei Samira, Chegene Lorestani Roya, Rezaeeniya Fatemeh, Mashreghi Farzad, Mohammadi Pourya, Rezaei Mansour, Rostamian Mosayeb, Motamed Hajar
Аннотация
OBJECTIVES: This study aimed to evaluate the concurrent effects of consuming Rhamnosus probiotics and oral antifungal Nystatin on inhibiting Candida (C.) albicans colonization in infants weighing <2,500 grams.
MATERIALS: This study was a randomized controlled clinical trial conducted on 104 infants born weighing <2,500 grams at Mohammad Kermanshahi Hospital in Kermanshah in 2021-22. The infants were randomly allocated into intervention (n=52) and control (n=52) groups. The control group received a placebo, 10 drops orally four times daily. In contrast, the intervention group received oral Nystatin 100,000 units 10 drops three times a day, combined with Rhamnosus Lactobacillus oral drops once daily for 7 to 10 days.
RESULTS: The results showed a lower frequency of positive C. albicans cultures in stool samples on the 7th day of age in the intervention group. Moreover, several variables such as the onset of nutrition, time to reach 100 ml/kg of milk intake per day, number of nil per os (NPO; "nothing through the mouth") episodes, total NPO time during hospitalization, episodes of intolerance until discharge, and duration of hospitalization were significantly lower in the intervention group compared to the control.
DISCUSSION: The concurrent use of Rhamnosus probiotics and oral Nystatin can lead to a reduction of positive C. albicans stool culture results, average time for certain variables such as the onset of nutrition, time to reach 100 ml/kg of milk intake per day, NPO days, total NPO time during hospitalization, episodes of intolerance until discharge, and duration of hospitalization in infants weighing <2,500 grams. Hence, their simultaneous administration is recommended for these neonates.
MATERIALS: This study was a randomized controlled clinical trial conducted on 104 infants born weighing <2,500 grams at Mohammad Kermanshahi Hospital in Kermanshah in 2021-22. The infants were randomly allocated into intervention (n=52) and control (n=52) groups. The control group received a placebo, 10 drops orally four times daily. In contrast, the intervention group received oral Nystatin 100,000 units 10 drops three times a day, combined with Rhamnosus Lactobacillus oral drops once daily for 7 to 10 days.
RESULTS: The results showed a lower frequency of positive C. albicans cultures in stool samples on the 7th day of age in the intervention group. Moreover, several variables such as the onset of nutrition, time to reach 100 ml/kg of milk intake per day, number of nil per os (NPO; "nothing through the mouth") episodes, total NPO time during hospitalization, episodes of intolerance until discharge, and duration of hospitalization were significantly lower in the intervention group compared to the control.
DISCUSSION: The concurrent use of Rhamnosus probiotics and oral Nystatin can lead to a reduction of positive C. albicans stool culture results, average time for certain variables such as the onset of nutrition, time to reach 100 ml/kg of milk intake per day, NPO days, total NPO time during hospitalization, episodes of intolerance until discharge, and duration of hospitalization in infants weighing <2,500 grams. Hence, their simultaneous administration is recommended for these neonates.